The Chemours Company (NYSE:CC - Free Report) - Zacks Research decreased their Q4 2025 EPS estimates for shares of Chemours in a report issued on Wednesday, July 9th. Zacks Research analyst R. Department now anticipates that the specialty chemicals company will earn $0.30 per share for the quarter, down from their previous forecast of $0.34. The consensus estimate for Chemours' current full-year earnings is $2.03 per share.
Several other research firms have also recently issued reports on CC. Morgan Stanley decreased their target price on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. Royal Bank Of Canada boosted their target price on shares of Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Thursday, July 3rd. UBS Group decreased their target price on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Mizuho set a $15.00 target price on shares of Chemours in a research note on Tuesday, April 15th. Finally, Wall Street Zen cut shares of Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $17.33.
View Our Latest Analysis on CC
Chemours Stock Performance
CC opened at $14.05 on Friday. The company has a debt-to-equity ratio of 7.01, a current ratio of 1.75 and a quick ratio of 0.83. The firm has a fifty day moving average price of $11.36 and a 200 day moving average price of $13.99. Chemours has a 1 year low of $9.13 and a 1 year high of $25.54. The stock has a market cap of $2.10 billion, a P/E ratio of 70.23 and a beta of 1.65.
Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.06). The business had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a net margin of 0.54% and a return on equity of 23.82%. The firm's revenue was up .4% on a year-over-year basis. During the same period last year, the company earned $0.32 earnings per share.
Institutional Investors Weigh In On Chemours
A number of large investors have recently modified their holdings of CC. Norges Bank purchased a new stake in shares of Chemours in the fourth quarter valued at about $30,702,000. Millennium Management LLC grew its holdings in shares of Chemours by 60.4% in the first quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company's stock valued at $54,428,000 after purchasing an additional 1,515,520 shares during the period. Vanguard Group Inc. grew its holdings in shares of Chemours by 8.3% in the first quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company's stock valued at $223,069,000 after purchasing an additional 1,263,047 shares during the period. Bank of Montreal Can grew its holdings in shares of Chemours by 1,496.4% in the fourth quarter. Bank of Montreal Can now owns 953,240 shares of the specialty chemicals company's stock valued at $16,110,000 after purchasing an additional 893,530 shares during the period. Finally, Ameriprise Financial Inc. grew its holdings in shares of Chemours by 23.8% in the fourth quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock valued at $73,907,000 after purchasing an additional 839,849 shares during the period. Hedge funds and other institutional investors own 76.26% of the company's stock.
Insiders Place Their Bets
In other Chemours news, insider Damian Gumpel bought 7,822 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was acquired at an average price of $9.95 per share, with a total value of $77,828.90. Following the completion of the acquisition, the insider directly owned 131,701 shares of the company's stock, valued at $1,310,424.95. This represents a 6.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Shane Hostetter bought 4,450 shares of the company's stock in a transaction dated Monday, May 19th. The shares were acquired at an average cost of $11.28 per share, with a total value of $50,196.00. Following the acquisition, the chief financial officer directly owned 59,694 shares of the company's stock, valued at approximately $673,348.32. This represents a 8.06% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 25,672 shares of company stock valued at $251,573 in the last ninety days. Insiders own 0.47% of the company's stock.
Chemours Dividend Announcement
The firm also recently announced a dividend, which was paid on Monday, June 16th. Stockholders of record on Monday, May 19th were issued a dividend of $0.0875 per share. This represents a dividend yield of 3.17%. The ex-dividend date was Friday, May 16th. Chemours's payout ratio is 175.00%.
Chemours Company Profile
(
Get Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report